Strontium Ranelate Reduces Vertebral Fracture Risk in Young Postmenopausal Women
Author Information
Author(s): C Roux, J Fechtenbaum, S Kolta, G Isaia, J B Cannata, J-P Devogelaer
Primary Institution: AP-HP Hôpital Cochin, Université Paris-Descartes, Paris, France
Hypothesis
Does strontium ranelate reduce the risk of vertebral fractures in young postmenopausal women with severe osteoporosis?
Conclusion
Strontium ranelate significantly reduces the risk of vertebral fractures in young postmenopausal women aged 50–65 years with severe osteoporosis.
Supporting Evidence
- Strontium ranelate reduced the risk of vertebral fractures by 35% over 4 years.
- Bone mineral density increased significantly in the strontium ranelate group compared to placebo.
- The study included 353 women aged 50-65 years with severe osteoporosis.
Takeaway
This study found that a medicine called strontium ranelate helps prevent broken bones in younger women who have weak bones after menopause.
Methodology
The study was a double-blind, placebo-controlled trial assessing the efficacy of strontium ranelate in reducing vertebral fractures over 4 years.
Potential Biases
There may be risks of bias due to the study design and the specific population selected.
Limitations
The study focused only on women aged 50-65 years, which may limit the generalizability of the results to other populations.
Participant Demographics
Participants were young postmenopausal women aged 50-65 years with severe osteoporosis.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI 0.42 to 0.99
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website